ABCL News and Press, AbCellera Biologics Inc. From 11/02/22

AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development. The pa...

AbCellera (Nasdaq: ABCL) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed thr...

AbCellera (Nasdaq: ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8 to 12, 2022. “T-cell engagers have tremendous potential...

Summary Stanley Druckenmiller’s 13F portfolio value decreased from $2.65B to $1.63B this quarter. Duquesne added Eli Lilly and CrowdStrike while reducing Microsoft, Freeport-McMoRan, and Teck Resources. They also dropped Amazon.com. The top three positions are at ~34% o...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Summary It's our belief that insiders supply the market with high-quality investment information each time they decide to trade their own company's shares on the open market. A central guidepost of modern finance is that the better-informed investor has the ability to deliver mark...

AbCellera ( NASDAQ: ABCL ) said on Wednesday it had launched the second phase of its global headquarters expansion with a new facility in Vancouver, Canada. ( ABCL ) has risen ~1% before the bell. The expansion will accommodate the growth of AbCelleraȁ...

AbCellera (Nasdaq: ABCL) today announced it has launched the second phase of its global headquarters expansion by breaking ground on its new facility in Vancouver, Canada. The 380,000-square-foot tech campus will include state-of-the-art lab and office spaces to support AbCellera&#x...

Summary AbCellera Biologics is an undervalued, profitable, drug discovery stock with a $3B market cap. AbCellera Biologics has a flawless balance sheet with no debt in the last five years and $1.1B in cash and cash equivalents. This company has capital and operational efficien...

AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to fur...